MX2023005663A - Tratamientos respiratorios. - Google Patents
Tratamientos respiratorios.Info
- Publication number
- MX2023005663A MX2023005663A MX2023005663A MX2023005663A MX2023005663A MX 2023005663 A MX2023005663 A MX 2023005663A MX 2023005663 A MX2023005663 A MX 2023005663A MX 2023005663 A MX2023005663 A MX 2023005663A MX 2023005663 A MX2023005663 A MX 2023005663A
- Authority
- MX
- Mexico
- Prior art keywords
- compositions
- treatments
- humans
- respiratory treatments
- microcolins
- Prior art date
Links
- 238000011282 treatment Methods 0.000 title abstract 3
- 230000000241 respiratory effect Effects 0.000 title abstract 2
- 239000000203 mixture Substances 0.000 abstract 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 108010028921 Lipopeptides Proteins 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 239000012636 effector Substances 0.000 abstract 1
- 210000003979 eosinophil Anatomy 0.000 abstract 1
- 230000002757 inflammatory effect Effects 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 229930192023 microcolin Natural products 0.000 abstract 1
- 150000003431 steroids Chemical class 0.000 abstract 1
- 238000011477 surgical intervention Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/10—Tetrapeptides
- C07K5/1002—Tetrapeptides with the first amino acid being neutral
- C07K5/1005—Tetrapeptides with the first amino acid being neutral and aliphatic
- C07K5/101—Tetrapeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms, e.g. Val, Ile, Leu
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/12—Aerosols; Foams
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06008—Dipeptides with the first amino acid being neutral
- C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
- C07K5/06026—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atom, i.e. Gly or Ala
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06008—Dipeptides with the first amino acid being neutral
- C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
- C07K5/06034—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06008—Dipeptides with the first amino acid being neutral
- C07K5/06078—Dipeptides with the first amino acid being neutral and aromatic or cycloaliphatic
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/10—Tetrapeptides
- C07K5/1002—Tetrapeptides with the first amino acid being neutral
- C07K5/1005—Tetrapeptides with the first amino acid being neutral and aliphatic
- C07K5/1008—Tetrapeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atoms, i.e. Gly, Ala
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/10—Tetrapeptides
- C07K5/1002—Tetrapeptides with the first amino acid being neutral
- C07K5/1016—Tetrapeptides with the first amino acid being neutral and aromatic or cycloaliphatic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Virology (AREA)
- Engineering & Computer Science (AREA)
- Dispersion Chemistry (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pulmonology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Immunology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063114976P | 2020-11-17 | 2020-11-17 | |
| US202163211972P | 2021-06-17 | 2021-06-17 | |
| PCT/US2021/059416 WO2022108883A1 (en) | 2020-11-17 | 2021-11-15 | Respiratory treatments |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2023005663A true MX2023005663A (es) | 2023-05-26 |
Family
ID=81709617
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2023005663A MX2023005663A (es) | 2020-11-17 | 2021-11-15 | Tratamientos respiratorios. |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20240002436A1 (https=) |
| EP (1) | EP4247165A4 (https=) |
| JP (1) | JP2023549855A (https=) |
| KR (1) | KR20230110295A (https=) |
| AU (1) | AU2021383599A1 (https=) |
| CA (1) | CA3199088A1 (https=) |
| MX (1) | MX2023005663A (https=) |
| TW (1) | TW202233647A (https=) |
| WO (1) | WO2022108883A1 (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2025101524A1 (en) * | 2023-11-06 | 2025-05-15 | Hbc Immunology Inc. | Lipopeptide compounds, and use in modulating eosinophilia |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2546164B1 (fr) * | 1983-05-16 | 1987-07-17 | Centre Nat Rech Scient | Nouveaux derives de peptides, leur preparation et leur application comme inhibiteurs de l'elastase |
| JPH0611754B2 (ja) * | 1985-10-09 | 1994-02-16 | サントリー株式会社 | ペプチダ−ゼ阻害作用を有する新規化合物及びその製法並びに用途 |
| EP0201743B1 (en) * | 1985-04-16 | 1992-04-01 | Suntory Limited | Dipeptide derivatives of fatty acids, process for preparing them, pharmaceutical composition and use |
| AU2003250586B2 (en) * | 2002-08-12 | 2010-09-23 | The Council Of The Queensland Institute Of Medical Research | Novel immunogenic lipopeptides comprising T-helper and B-cell epitopes |
| WO2009046220A2 (en) * | 2007-10-02 | 2009-04-09 | Mdrna, Inc. | Lipopeptides for delivery of nucleic acids |
| KR101250812B1 (ko) * | 2011-03-18 | 2013-04-04 | 미원상사주식회사 | 언데세노일 디펩타이드 유도체 및 이를 함유하는 피부미백용 화장료 조성물 |
| US20140154257A1 (en) * | 2012-06-07 | 2014-06-05 | Luanne Robalo DeChristopher | Materials and methods for diagnosing and treating asthma and dietary Fru-AGEs related disorders including auto-immune and other diseases found to be associated with elevated RAGE. The specification describes methods to identify and make dietary derived advanced glycation end-products, known as Fru-AGEs, Fru-AGE-haptens, and Fru-AGE immune complexes, and to make monoclonal and polyclonal antibodies to this plurality of bio-molecules for use in immunoassays and for use as therapeutic agents |
| US9371276B1 (en) * | 2015-03-21 | 2016-06-21 | Mohan Murali Alapati | Compositions and methods for the treatment of hyperglycemia and metabolic syndrome |
| WO2017068477A1 (en) * | 2015-10-18 | 2017-04-27 | Rao M Surya | Compound, composition and uses thereof |
-
2021
- 2021-11-12 TW TW110142132A patent/TW202233647A/zh unknown
- 2021-11-15 US US18/036,382 patent/US20240002436A1/en active Pending
- 2021-11-15 MX MX2023005663A patent/MX2023005663A/es unknown
- 2021-11-15 EP EP21895419.6A patent/EP4247165A4/en active Pending
- 2021-11-15 CA CA3199088A patent/CA3199088A1/en active Pending
- 2021-11-15 AU AU2021383599A patent/AU2021383599A1/en active Pending
- 2021-11-15 WO PCT/US2021/059416 patent/WO2022108883A1/en not_active Ceased
- 2021-11-15 JP JP2023528658A patent/JP2023549855A/ja active Pending
- 2021-11-15 KR KR1020237019970A patent/KR20230110295A/ko active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| WO2022108883A1 (en) | 2022-05-27 |
| CA3199088A1 (en) | 2022-05-27 |
| US20240002436A1 (en) | 2024-01-04 |
| AU2021383599A1 (en) | 2023-05-25 |
| KR20230110295A (ko) | 2023-07-21 |
| EP4247165A4 (en) | 2025-01-22 |
| AU2021383599A9 (en) | 2024-02-08 |
| EP4247165A1 (en) | 2023-09-27 |
| JP2023549855A (ja) | 2023-11-29 |
| TW202233647A (zh) | 2022-09-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2023003677A (es) | Inhibidores de hidroxiesteroide 17beta- deshidrogenasa 13 (hsd17b13) y usos de estos. | |
| PH12018502634A1 (en) | Topical compositions of apremilast | |
| MX2023003678A (es) | Inhibidores de hidroxiesteroide 17beta- deshidrogenasa 13 (hsd17b13) y usos de estos. | |
| NZ745678A (en) | Compositions comprising bacterial blautia strains for treating visceral hypersensitivity | |
| BR112023018472A2 (pt) | Composições de psilocibina, métodos de produção e métodos de uso das mesmas | |
| PH12020551905A1 (en) | C-mannoside compounds useful for the treatment of urinary tract infections | |
| JOP20220259A1 (ar) | تركيبات تشتمل على جسيمات نانونية، طريقة تصنيعها واستخدامها | |
| NO20063047L (no) | Vandige ciclesonidsuspensjoner for forstoving | |
| CL2023000296A1 (es) | Uso de dexpramipexol para el tratamiento del asma moderado a grave | |
| EA202193190A1 (ru) | Композиция, включающая придопидин и его аналог, для лечения болезни гентингтона и ее симптомов | |
| MX2021003681A (es) | Composiciones y metodos para el tratamiento de desordenes inflamatorios. | |
| MX2023012875A (es) | Inhibidores 2-fluoro alquil-l,3,4-oxadiazol-5-il-tiazol de hdac6 para su uso en el tratamiento de enfermedades metabólicas y hfpef. | |
| MX2023010711A (es) | Fenalquilaminas y métodos de preparación y uso de las mismas. | |
| MX2023003675A (es) | Inhibidores de hidroxiesteroide 17beta-deshidrogenasa 13 (hsd17b13) y usos de estos. | |
| WO2022047128A3 (en) | Method for treating complement mediated disorders caused by betacoronaviruses | |
| JOP20230218A1 (ar) | مشتقات بيرازولو بيريدين واستخداماتها | |
| WO2022192594A3 (en) | Nucleic acid molecules and vaccines comprising same for the prevention and treatment of coronavirus infections and disease | |
| WO2024099364A3 (en) | Fused multicyclic compounds and their use as parp1 inhibitors | |
| WO2021022058A3 (en) | Antiarrhythmic formulation | |
| MX2022012001A (es) | Tratamiento preventivo de la migra?a. | |
| WO2022178255A3 (en) | Single domain antibodies that neutralize sars-cov-2 | |
| MX2023005663A (es) | Tratamientos respiratorios. | |
| WO2021242844A8 (en) | Grk2 inhibitors and uses thereof | |
| BR112023001121A2 (pt) | Cepa c de prevotella histicola como uma terapia oral para doenças inflamatórias | |
| MX2021005423A (es) | Macrolidos de 13 miembros sustituidos con c10-alquileno y usos de los mismos. |